Bank of America Corp DE Buys 92,830 Shares of AtriCure, Inc. $ATRC

Key Points

• Bank of America increased its AtriCure stake by 13.7% in the first quarter, buying 92,830 shares to hold 768,561 shares valued at approximately $21.9 million. Institutional investors collectively own 99.11% of the company.
• AtriCure reported quarterly EPS of $0.18 on $153.6 million in revenue, exceeding analyst expectations, and issued fiscal 2026 EPS guidance of $0.24 to $0.32.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $48.50, although company insiders have sold 44,246 shares worth about $1.69 million over the past three months.

Bank of America Corp DE grew its stake in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 13.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 768,561 shares of the medical device company's stock after buying an additional 92,830 shares during the quarter. Bank of America Corp DE owned approximately 1.52% of AtriCure worth $21,927,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. F m Investments LLC bought a new stake in AtriCure during the fourth quarter valued at about $2,872,000. Vanguard Group Inc. boosted its stake in shares of AtriCure by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 4,903,755 shares of the medical device company's stock worth $193,993,000 after acquiring an additional 62,861 shares during the period. Arrowstreet Capital Limited Partnership purchased a new stake in shares of AtriCure during the first quarter worth about $7,922,000. California State Teachers Retirement System grew its position in shares of AtriCure by 33.3% during the first quarter. California State Teachers Retirement System now owns 59,947 shares of the medical device company's stock worth $1,710,000 after purchasing an additional 14,987 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in AtriCure by 8.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 997,759 shares of the medical device company's stock valued at $28,466,000 after purchasing an additional 75,862 shares during the period. Institutional investors own 99.11% of the company's stock.

AtriCure Price Performance

Shares of ATRC stock opened at $45.76 on Wednesday. The company has a market capitalization of $2.33 billion, a P/E ratio of 217.92 and a beta of 1.20. The company's 50-day simple moving average is $34.64 and its two-hundred day simple moving average is $31.57. AtriCure, Inc. has a one year low of $25.36 and a one year high of $46.34. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The business had revenue of $153.60 million during the quarter, compared to analyst estimates of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same period in the previous year, the company posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, equities analysts anticipate that AtriCure, Inc. will post 0.2 EPS for the current year.

Insider Buying and Selling at AtriCure

In related news, Director Karen Prange sold 3,564 shares of the company's stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total transaction of $138,283.20. Following the completion of the sale, the director directly owned 22,809 shares in the company, valued at $884,989.20. This represents a 13.51% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Justin J. Noznesky sold 6,182 shares of the firm's stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total value of $239,861.60. Following the sale, the insider directly owned 100,219 shares in the company, valued at approximately $3,888,497.20. The trade was a 5.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 44,246 shares of company stock worth $1,691,895. 4.00% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ATRC has been the topic of several recent analyst reports. Raymond James Financial set a $52.00 price objective on shares of AtriCure in a research report on Tuesday, July 21st. Citigroup restated a "market outperform" rating on shares of AtriCure in a research report on Tuesday, July 21st. Zacks Research upgraded shares of AtriCure from a "hold" rating to a "strong-buy" rating in a research report on Friday, July 24th. UBS Group lowered their price target on shares of AtriCure from $55.00 to $50.00 and set a "buy" rating for the company in a report on Tuesday, July 28th. Finally, Wall Street Zen lowered AtriCure from a "strong-buy" rating to a "buy" rating in a research report on Saturday, May 2nd. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, AtriCure has a consensus rating of "Moderate Buy" and an average price target of $48.50.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company's solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company's product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source